Recurrent Melanoma Terminated Phase 2 Trials for RG-4733 (DB11870)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01120275Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV MelanomaTreatment